Last reviewed · How we verify
OCL 500 Treatment of Women With Symptomatic Uterine Fibroids
This is a prospective, open-label, single-arm, safety and effectiveness study of Occlusin 500 microspheres in women with symptomatic uterine fibroids.
Details
| Lead sponsor | IMBiotechnologies Ltd. |
|---|---|
| Phase | NA |
| Status | COMPLETED |
| Enrolment | 12 |
| Start date | Wed Jan 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Uterine Fibroid
- Myoma
- Leiomyoma
Interventions
- Occlusin 500 Microspheres
Countries
Canada